Vitamin D deficiency in first episode psychosis: A case-control study

Schizophrenia Research

Volumn 150, Issue 2-3, 2013, Pages 533-537

  Crews, Matthieu ^a,b   Lally, John ^b,c   Gardner Sood, Poonam ^b   Howes, Oliver ^b   Bonaccorso, Stefania ^b   Smith, Shubulade ^b,c   Murray, Robin M ^b,c   Di Forti, Marta ^b   Gaughran, Fiona ^b,c  

^a OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

25 Hydroxyvitamin D; Case control study; Ethnicity; First episode psychosis; Schizophrenia; Vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D;

ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNICITY; GENDER; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOSIS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

25-HYDROXYVITAMIN D; CASE-CONTROL STUDY; ETHNICITY; FIRST EPISODE PSYCHOSIS; SCHIZOPHRENIA; VITAMIN D DEFICIENCY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84886235711     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.08.036     Document Type: Article

References (56)

1. Almeras L., Eyles D., Benech P., Laffite D., Villard C., Patatian A., Boucraut J., Mackay-Sim A., McGrath J., Feron F. Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Proteomics 2007, 7(5):769-780.
2. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67(2):146-154.
3. Bebbington P.E., Nayani T. The Psychosis Screening Questionnaire. Int. J. Methods Psychiatr. Res. 1995, 5:11-19.
4. Berg A.O., Melle I., Torjesen P.A., Lien L., Hauff E., Andreassen O.A. A cross-sectional study of vitamin D deficiency among immigrants and Norwegians with psychosis compared to the general population. J. Clin. Psychiatry 2010, 71(12):1598-1604.
5. Berk M., Jacka F.N., Williams L.J., Ng F., Dodd S., Pasco J.A. Is this D vitamin to worry about? Vitamin D insufficiency in an inpatient sample. Aust. N. Z. J. Psychiatry 2008, 42(10):874-878.
6. Bischoff-Ferrari H.A. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv. Exp. Med. Biol. 2008, 624:55-71.
7. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 2006, 84(1):18-28.
8. Boonen S., Bischoff-Ferrari H.A., Cooper C., Lips P., Ljunggren O., Meunier P.J., Reginster J.Y. Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif. Tissue Int. 2006, 78(5):257-270.
9. Brot C., Jorgensen N.R., Sorensen O.H. The influence of smoking on vitamin D status and calcium metabolism. Eur. J. Clin. Nutr. 1999, 53(12):920-926.
10. Chang C.-K., Hayes R.D., Perera G., Broadbent M.T.M., Fernandes A.C., Lee W.E., Hotopf M., Stewart R. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS One 2011, 6(5):1-6.
11. Cutillas-Marco E., Fuertes-Prosper A., Grant W.B., Morales-Suarez-Varela M. Vitamin D deficiency in South Europe: effect of smoking and aging. Photodermatol. Photoimmunol. Photomed. 2012, 28(3):159-161.
12. Eyles D.W., Burne T.H., McGrath J.J. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front. Neuroendocrinol. 2013, 34(1):47-64.
13. Ford L., Graham V., Wall A., Berg J. Vitamin D concentrations in an UK inner-city multicultural outpatient population. Ann. Clin. Biochem. 2006, 43(Pt 6):468-473.
14. Fuller K.E., Casparian J.M. Vitamin D: balancing cutaneous and systemic considerations. South. Med. J. 2001, 94(1):58-64.
15. Gama R., Waldron J.L., Ashby H.L., Cornes M.P., Bechervaise J., Razavi C., Thomas O.L., Chugh S., Deshpande S., Ford C. Hypovitaminosis D and disease: consequence rather than cause?. BMJ 2012, 345. (e5706-e5706).
16. Grandi N.C., Breitling L.P., Brenner H. Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev. Med. 2010, 51(3-4):228-233.
17. Groves N.J., Kesby J.P., Eyles D.W., McGrath J.J., Mackay-Sim A., Burne T.H. Adult vitamin D deficiency leads to behavioural and brain neurochemical alterations in C57BL/6J and BALB/c mice. Behav. Brain Res. 2013, 241:120-131.
18. Harvey N.C., Cooper C. Vitamin D: some perspective please. BMJ 2012, 345:e4695. (Jul 19). 10.1136/bmj.e4695.
19. Hermann A.P., Brot C., Gram J., Kolthoff N., Mosekilde L. Premenopausal smoking and bone density in 2015 perimenopausal women. J. Bone Miner. Res. 2000, 15(4):780-787.
20. Hewison M. Vitamin D and innate and adaptive immunity. Vitam. Horm. 2011, 86:23-62.
21. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 2004, 80(6 Suppl.):1678S-1688S.
22. Holick M.F. Diabetes and the vitamin D connection. Curr. Diab. Rep. 2008, 8(5):393-398.
23. Honasoge M., Rao D.S. Metabolic bone disease in gastrointestinal, hepatobiliary, and pancreatic disorders and total parenteral nutrition. Curr. Opin. Rheumatol. 1995, 7(3):249-254.
24. Humble M.B., Gustafsson S., Bejerot S. Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric out-patients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis. J. Steroid Biochem. Mol. Biol. 2010, 121(1-2):467-470.
25. Hypponen E., Power C. Hypovitaminosis D in British adults at age 45y: nationwide cohort study of dietary and lifestyle predictors. Am. J. Clin. Nutr. 2007, 85(3):860-868.
26. Iuliano-Burns S., Wang X.F., Ayton J., Jones G., Seeman E. Skeletal and hormonal responses to sunlight deprivation in Antarctic expeditioners. Osteoporos. Int. 2009, 20(9):1523-1528.
27. Klontz K.C., Acheson D.W. Dietary supplement-induced vitamin D intoxication. N. Engl. J. Med. 2007, 357(3):308-309.
28. Lally J., Gardner-Sood P., Howes O., Smith S., Atakan Z., Greenwood K., Murray R.M., Gaughran F. Vitamin D Deficiency in Schizophrenia-A Need for Increased Vigilance?. International Congress on Schizophrenia Research (ICOS-R), Orlando, Florida 2013.
29. Looker A.C., Dawson-Hughes B., Calvo M.S., Gunter E.W., Sahyoun N.R. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002, 30(5):771-777.
30. Looker A.C., Pfeiffer C.M., Lacher D.A., Schleicher R.L., Picciano M.F., Yetley E.A. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am. J. Clin. Nutr. 2008, 88(6):1519-1527.
31. McCann J.C., Ames B.N. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?. FASEB J. 2008, 22(4):982-1001.
32. McGrath J. Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia?. Schizophr. Res. 1999, 40(3):173-177.
33. McGrath J., Saari K., Hakko H., Jokelainen J., Jones P., Jarvelin M.R., Chant D., Isohanni M. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr. Res. 2004, 67(2-3):237-245.
34. McGrath J.J., Burne T.H., Féron F., Mackay-Sim A., Eyles D.W. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophr. Bull. 2010, 36(6):1073-1078.
35. McGrath J.J., Eyles D.W., Pedersen C.B., Anderson C., Ko P., Burne T.H., Norgaard-Pedersen B., Hougaard D.M., Mortensen P.B. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch. Gen. Psychiatry 2010, 67(9):889-894.
36. McGrath J., Brown A., St Clair D. Prevention and schizophrenia-the role of dietary factors. Schizophr. Bull. 2011, 37(2):272-283.
37. Meaney A.M., Smith S., Howes O.D., O'brien M., Murray R.M., O'keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br. J. Psychiatry 2004, 184(6):503-508.
38. Menkes D.B., Lancaster K., Grant M., Marsh R.W., Dean P., du Toit S.A. Vitamin D status of psychiatric inpatients in New Zealand's Waikato region. BMC Psychiatry 2012, 12:68.
39. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
40. Mithal A., Wahl D.A., Bonjour J.P., Burckhardt P., Dawson-Hughes B., Eisman J.A., El-Hajj Fuleihan G., Josse R.G., Lips P., Morales-Torres J. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos. Int. 2009, 20(11):1807-1820.
41. Orton S.M., Ramagopalan S.V., Para A.E., Lincoln M.R., Handunnetthi L., Chao M.J., Morahan J., Morrison K.M., Sadovnick A.D., Ebers G.C. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J. Neurol. Sci. 2011, 305(1-2):116-120.
42. Pack A.M., Gidal B., Vazquez B. Bone disease associated with antiepileptic drugs. Cleve. Clin. J. Med. 2004, 71(2):S42-S48.
43. Pearce S.H., Cheetham T.D. Diagnosis and management of vitamin D deficiency. BMJ 2010, 11(340):142-147.
44. Rosen C.J. Clinical practice. Vitamin D insufficiency. N. Engl. J. Med. 2011, 364(3):248-254.
45. Skversky A.L., Kumar J., Abramowitz M.K., Kaskel F.J., Melamed M.L. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006. J. Clin. Endocrinol. Metab. 2011, 96(12):3838-3845.
46. Tiangga E., Gowda A., Dent J.A. Vitamin D deficiency in psychiatric in-patients and treatment with daily supplements of calcium and ergocalciferol. Psychiatr. Bull. 2008, 32(10):390-393.
47. Verrotti A., Coppola G., Parisi P., Mohn A., Chiarelli F. Bone and calcium metabolism and antiepileptic drugs. Clin. Neurol. Neurosurg. 2010, 112(1):1-10.
48. Vimaleswaran K.S., Berry D.J., Lu C., Tikkanen E., Pilz S., Hiraki L.T., Cooper J.D., Dastani Z., Li R., Houston D.K., Wood A.R., Michaëlsson K., Vandenput L., Zgaga L., Yerges-Armstrong L.M., McCarthy M.I., Dupuis J., Kaakinen M., Kleber M.E., Jameson K., Arden N., Raitakari O., Viikari J., Lohman K.K., Ferrucci L., Melhus H., Ingelsson E., Byberg L., Lind L., Lorentzon M., Salomaa V., Campbell H., Dunlop M., Mitchell B.D., Herzig K.-H., Pouta A., Hartikainen A.-L., Streeten E.A., Theodoratou E., Jula A., Wareham N.J., Ohlsson C., Frayling T.M., Kritchevsky S.B., Spector T.D., Richards J.B., Lehtimäki T., Ouwehand W.H., Kraft P., Cooper C., März W., Power C., Loos R.J.F., Wang T.J., Järvelin M.-R., Whittaker J.C., Hingorani A.D., Hyppönen E., The Genetic Investigation of Anthropometric Traits Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med. 2013, 10(2):1-13.
49. Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., Benjamin E.J., D'Agostino R.B., Wolf M., Vasan R.S. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117(4):503-511.
50. Wang L., Song Y., Manson J.E., Pilz S., Marz W., Michaelsson K., Lundqvist A., Jassal S.K., Barrett-Connor E., Zhang C., Eaton C.B., May H.T., Anderson J.L., Sesso H.D. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ. Cardiovasc. Qual. Outcomes 2012, 5(6):819-829.
51. Wharton B., Bishop N. Rickets. Lancet 2003, 362(9393):1389-1400.
52. White T., Anjum A., Schulz C. The schizophrenia prodrome. Am. J. Psychiatry 2006, 163:376-380.
53. Wood H. Multiple sclerosis: sunlight and vitamin D influence multiple sclerosis risk independently of HLA-DRB1[ast]15 status. Nat. Rev. Neurol. 2012, 8(3):122-122.
54. World Health Organisation WHO Scientific Group on the Prevention and Management of Osteoporosis: Report of a WHO Scientific Group 2003, World Health Organisation, Geneva.
55. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., Holick M.F. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 2000, 72(3):690-693.
56. Zadshir A., Tareen N., Pan D., Norris K., Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn. Dis. 2005, 15(Suppl. 4-5):97-101.